These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 37194022)

  • 1. Crosstalk between the JAK2 and TGF-β1 signaling pathways in scleroderma-related interstitial lung disease targeted by baricitinib.
    Wang D; Wei Y; Xu L; Zhang J
    Adv Rheumatol; 2023 May; 63(1):22. PubMed ID: 37194022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cysteine proteinase inhibitor ALLN alleviates bleomycin-induced skin and lung fibrosis.
    Kasamatsu H; Chino T; Hasegawa T; Utsunomiya N; Utsunomiya A; Yamada M; Oyama N; Hasegawa M
    Arthritis Res Ther; 2023 Aug; 25(1):156. PubMed ID: 37626391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COA-Cl prevented TGF-β1-induced CTGF expression by Akt dephosphorylation in normal human dermal fibroblasts, and it attenuated skin fibrosis in mice models of systemic sclerosis.
    Nakai K; Karita S; Igarashi J; Tsukamoto I; Hirano K; Kubota Y
    J Dermatol Sci; 2019 Apr; 94(1):205-212. PubMed ID: 30954335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iguratimod inhibits skin fibrosis by regulating TGF-β1/Smad signalling pathway in systemic sclerosis.
    Xie X; Gan H; Tian J; Li F; Chen J; Wang J; Liao J; Li S
    Eur J Clin Invest; 2022 Aug; 52(8):e13791. PubMed ID: 35441708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of thalidomide on Th17, Treg cells and TGF-β1/Smad3 pathway in a mouse model of systemic sclerosis.
    Lu Y; Zhao C; Lei L; Tao Z; Zheng L; Wen J; Li X
    Int J Rheum Dis; 2020 Mar; 23(3):406-419. PubMed ID: 31840939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β1 Signaling Pathway.
    Gu S; Liang J; Zhang J; Liu Z; Miao Y; Wei Y; Li S; Gu J; Cui Y; Xiao T; Li X; Yang C
    Molecules; 2023 Feb; 28(5):. PubMed ID: 36903446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid cell-specific deletion of Capns1 prevents macrophage polarization toward the M1 phenotype and reduces interstitial lung disease in the bleomycin model of systemic sclerosis.
    Zhang L; Zheng D; Yan Y; Yu Y; Chen R; Li Z; Greer PA; Peng T; Wang Q
    Arthritis Res Ther; 2022 Jun; 24(1):148. PubMed ID: 35729674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced Pulmonary Fibrosis.
    Sun H; Zhu Y; Pan H; Chen X; Balestrini JL; Lam TT; Kanyo JE; Eichmann A; Gulati M; Fares WH; Bai H; Feghali-Bostwick CA; Gan Y; Peng X; Moore MW; White ES; Sava P; Gonzalez AL; Cheng Y; Niklason LE; Herzog EL
    Arthritis Rheumatol; 2016 May; 68(5):1251-61. PubMed ID: 26749424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-β1 signaling.
    Lee CG; Herzog EL; Ahangari F; Zhou Y; Gulati M; Lee CM; Peng X; Feghali-Bostwick C; Jimenez SA; Varga J; Elias JA
    J Immunol; 2012 Sep; 189(5):2635-44. PubMed ID: 22826322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baricitinib improves pulmonary fibrosis in mice with rheumatoid arthritis-associated interstitial lung disease by inhibiting the Jak2/Stat3 signaling pathway.
    Liu H; Yang Y; Zhang J; Li X
    Adv Rheumatol; 2023 Aug; 63(1):45. PubMed ID: 37641106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulation of TNF-induced protein 3 and CCAAT/enhancer-binding protein β in alveolar macrophages: Implications for systemic sclerosis-associated interstitial lung disease.
    Hua X; Hongbing R; Juan X; Jizan L; Beibei Y
    Int J Rheum Dis; 2024 May; 27(5):e15174. PubMed ID: 38720423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-β1 Signaling Pathway.
    Ruan H; Luan J; Gao S; Li S; Jiang Q; Liu R; Liang Q; Zhang R; Zhang F; Li X; Zhou H; Yang C
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mouse model of progressive lung fibrosis with cutaneous involvement induced by a combination of oropharyngeal and osmotic minipump bleomycin delivery.
    Grandi A; Ferrini E; Zoboli M; Buseghin D; Pennati F; Khalajzeyqami Z; Ciccimarra R; Villetti G; Stellari FF
    Am J Physiol Lung Cell Mol Physiol; 2024 Jun; 326(6):L736-L753. PubMed ID: 38651940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of semaphorin 7a signaling in transforming growth factor β1-induced lung fibrosis and scleroderma-related interstitial lung disease.
    Gan Y; Reilkoff R; Peng X; Russell T; Chen Q; Mathai SK; Homer R; Gulati M; Siner J; Elias J; Bucala R; Herzog E
    Arthritis Rheum; 2011 Aug; 63(8):2484-94. PubMed ID: 21484765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease.
    Soldano S; Smith V; Montagna P; Gotelli E; Campitiello R; Pizzorni C; Paolino S; Sulli A; Cere A; Cutolo M
    Arthritis Res Ther; 2024 Mar; 26(1):74. PubMed ID: 38509595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baicalein alleviates fibrosis and inflammation in systemic sclerosis by regulating B-cell abnormalities.
    Peng B; Hu Q; He R; Hou H; Lian D; Chen Y; Li H; Song L; Gao Y; Chen T; Zhang G; Li J
    BMC Complement Med Ther; 2023 Feb; 23(1):62. PubMed ID: 36810081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Necrostatin-1 Alleviates Bleomycin-Induced Pulmonary Fibrosis and Extracellular Matrix Expression in Interstitial Pulmonary Fibrosis.
    Mou F; Mou C
    Med Sci Monit; 2020 Feb; 26():e919739. PubMed ID: 32019905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
    Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
    Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-155 in the progression of lung fibrosis in systemic sclerosis.
    Christmann RB; Wooten A; Sampaio-Barros P; Borges CL; Carvalho CR; Kairalla RA; Feghali-Bostwick C; Ziemek J; Mei Y; Goummih S; Tan J; Alvarez D; Kass DJ; Rojas M; de Mattos TL; Parra E; Stifano G; Capelozzi VL; Simms RW; Lafyatis R
    Arthritis Res Ther; 2016 Jul; 18(1):155. PubMed ID: 27377409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.